Iron chelators in cancer chemotherapy

Current Topics in Medicinal Chemistry

Volumn 4, Issue 15, 2004, Pages 1623-1635

  Buss, Joan L ^a   Greene, Bryan T ^a   Turner, JoLyn ^a   Torti, Frank M ^a   Torti, Suzy V ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Apoptosis; Cancer; Cell cycle; Cytotoxicity; Desferrioxamine; Drug design; Iron depletion; Ribonucleotide reductase

Indexed keywords

1 FORMYLISOQUINOLINE THIOSEMICARBAZONE; 1,2 PROPANEDIAMINE N,N' DIACETAMIDE N,N' DIACETIC ACID; 2 HYDROXY 1 NAPHTHYLALDEHYDE ISONICOTINOYLHYDRAZONE; 3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 5 AMINO 4 METHYLISOQUINOLINE 1 CARBOXALDEHYDE THIOSEMICARBAZONE; 5 HYDROXYPICOLINALDEHYDE THIOSEMICARBAZONE; ANTHRACYCLINE DERIVATIVE; CICLOPIROXOLAMINE; DAUNORUBICIN; DEFEROXAMINE; DEFERRIFERRITHIOCIN; DITHIZONE; DOXORUBICIN; HYDROXYUREA; IRON CHELATING AGENT; IRON COMPLEX; MIMOSINE; N(G) METHYLARGININE; PROTOCATECHUIC ACID; PYRIDINE DERIVATIVE; PYRIDOXAL 3 FLUOROBENZOYLHYDRAZONE; PYRIDOXAL ISONICOTINOYLHYDRAZONE; QUINOLINOL DERIVATIVE; RAZOXANE; REACTIVE OXYGEN METABOLITE; TACHPYRIDINE; THIOSEMICARBAZONE DERIVATIVE; THUJAPLICIN; TRENSOX; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARDIOTOXICITY; CLINICAL TRIAL; COMPLEX FORMATION; CONGESTIVE HEART FAILURE; CYTOTOXICITY; DIZZINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; GASTROINTESTINAL TOXICITY; HUMAN; IN VITRO STUDY; IRON DEPLETION; IRON OVERLOAD; KIDNEY DYSFUNCTION; LEG CRAMP; LETHARGY; LIVER DYSFUNCTION; NEUROBLASTOMA; NONHUMAN; NUTRIENT; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; VISUAL DISORDER;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHELATION THERAPY; DEFEROXAMINE; HUMANS; IRON CHELATING AGENTS; NEOPLASMS;

EID: 10644257442     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043387269     Document Type: Review

References (172)

1. Chaston, T. B. and Richardson, D. R. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am. J. Hematol. 2003, 73, 200-210.
2. Buss, J. L.; Hermes-Lima, M.; and Ponka, P. Pyridoxal isonicotinoyl hydrazone and its analogues. In Iron Chelating Therapy Hershko, C. Ed.; Plenum Press: New York, 2002.
3. Reddy, B. R.; Kloner, R. A.; and Przyklenk, K. Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury. Free Rad. Biol. Med. 1989, 7, 45-52.
4. Ward, P. A.; Warren, J. S.; Till, G. O.; Varani, J.; and Johnson, K. J. Modification of disease by preventing free radical formation: a new concept in pharmacological intervention. Bailliere's Clin. Haematol. 1989, 2, 391-402.
5. Thompson, K. J.; Shoham, S.; and Connor, J. R. Iron and neurodegenerative disorders. Brain Res. Bull. 2001, 55, 155-164.
6. Gassen, M. and Youdim, M. B. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol. Toxicol. 1997, 80, 159-166.
7. Biemond, P.; Swaak, A. J.; van Eijk, H. G.; and Koster, J. F. Superoxide dependent iron release from ferritin in inflammatory diseases. Free Rad. Biol. Med. 1988, 4, 185-198.
8. Richardson, D. R. Iron chelators as therapeutic agents for the treatment of cancer. Crit. Rev. Oncol. Hematol. 2002, 42, 267-281.
9. Richardson, D. R. Potential of iron chelators as effective antiproliferative agents. Can. J. Physiol. Pharmacol. 1997, 75, 1164-1180.
10. Richardson, D. R. and Ponka, P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim. Biophys. Acta 1997, 1331, 1-40.
11. Aisen, P.; Enns, C.; and Wessling-Resnick, M. Chemistry and biology of eukaryotic iron metabolism. Int. J. Biochem. Cell Biol. 2001, 33, 940-959.
12. Gunshin, H.; Mackenzie, B.; Berger, U. V.; Gunshin, Y.; Romero, M. F.; Boron, W. F.; Nussberger, S.; Gollan, J. L.; and Hediger, M. A. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997, 388, 482-488.
13. Torti, F. M. and Torti, S. V. Regulation of ferritin genes and protein. Blood 2002, 99, 3505-3516.
14. Harrison, P. M. and Arosio, P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta 1996, 1275, 161-203.
15. Muhlenhoff, U. and Lill, R. Biogenesis of iron-sulfur proteins in eukaryotes: a novel task of mitochondria that is inherited from bacteria. Biochim. Biophys. Acta 2000, 1459, 370-382.
16. Guo, B.; Phillips, J. D.; Yu, Y.; and Leibold, E. A. Iron regulates the intracellular degradation of iron regulatory protein 2 by the proteasome. J. Biol. Chem. 1995, 270, 21645-21651.
17. Cooper, C. E.; Lynagh, G. R.; Hoyes, K. P.; Hider, R. C.; Cammack, R.; and Porter, J. B. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J. Biol. Chem. 1996, 271, 20291-20299.
18. Esposito, B. P.; Epsztejn, S.; Breuer, W.; and Cabantchik, Z. I. A review of fluorescence methods for assessing labile iron in cells and biological fluids. Anal. Biochem. 2002, 304, 1-18.
19. Buettner, G. R. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch. Biochem. Biophys. 1993, 300, 535-543.
20. Petrat, F.; de Groot, H.; and Rauen, U. Subcellular distribution of chelatable iron: a laser scanning microscopic study in isolated hepatocytes and liver endothelial cells. Biochem. J. 2001, 356, 61-69.
21. Faulk, W. P.; Hsi, B. L.; and Stevens, P. J. Transferrin and transferrin receptors in carcinoma of the breast. Lancet 1980 2, 390-392.
22. Basar, I.; Ayhan, A.; Bircan, K.; Ergen, A.; and Tasar, C. Transferrin receptor activity as a marker in transitional cell carcinoma of the bladder. Br. J. Urol. 1991, 67, 165-168.
23. Keer, H. N.; Kozlowski, J. M.; Tsai, Y. C.; Lee, C.; McEwan, R. N.; and Grayhack, J. T. Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo. J. Urol. 1990, 143, 381-385.
24. Sutherland, R.; Delia, D.; Schneider, C.; Newman, R.; Kemshead, J.; and Greaves, M. Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. Proc. Natl. Acad. Sci. USA 1981, 78, 4515-4519.
25. Larrick, J. W. and Cresswell, P. Modulation of cell surface iron transferrin receptors by cellular density and state of activation. J Supramol. Struct. 1979, 11, 579-586.
26. Wu, K. J.; Polack, A.; and Dalla-Favera, R. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. Science 1999, 283, 676-679.
27. Cairo, G.; Vezzoni, P.; Bardella, L.; Schiaffonati, L.; Rappocciolo, E.; Levi, S.; Arosio, P.; and Bernelli-Zazzera, A. Regulation of ferritin synthesis in malignant and non-malignant lymphoid cells. Biochem. Biophys. Res. Commun. 1986, 139, 652-657.
28. Vaughn, C. B.; Weinstein, R.; Bond, B.; Rice, R.; Vaughn, R. W.; McKendrick, A.; Ayad, G.; Rockwell, M. A.; and Rocchio, R. Ferritin content in human cancerous and noncancerous colonic tissue. Cancer Invest. 1987, 5, 7-10.
29. Williams, G. M. The pathogenesis of rat liver cancer caused by chemical carcinogens. Biochim. Biophys. Acta 1980, 605 167-189.
30. Linder, M.; Munro, H. N.; and Morris, H. P. Rat ferritin isoproteins and their response to iron administration in a series of hepatic tumors and in normal and regenerating liver. Cancer Res. 1970, 30, 2231-2239.
31. Hann, H. W.; Levy, H. M.; and Evans, A. E. Serum ferritin as a guide to therapy in neuroblastoma. Cancer Res. 1980, 40 1411-1413.
32. Hann, H. L.; Stahlhut, M. W.; and Millman, I. Human ferritins present in the sera of nude mice transplanted with human neuroblastoma or hepatocellular carcinoma. Cancer Res. 1984, 44, 3898-3901.
33. Konijn, A. M. Iron metabolism in inflammation. Bailliere's Clin. Haematol. 1994, 7, 829-849.
34. Stevens, R. G.; Jones, D. Y.; Micozzi, M. S.; and Taylor, P. R. Body iron stores and the risk of cancer. New Engl. J. Med. 1988, 319, 1047-1052.
35. Stevens, R. G.; Graubard, B. I.; Micozzi, M. S.; Neriishi, K.; and Blumberg, B. S. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int. J. Cancer 1994, 56, 364-369.
36. Siegers, C. P.; Bumann, D.; Trepkau, H. D.; Schadwinkel, B.; and Baretton, G. Influence of dietary iron overload on cell proliferation and intestinal tumorigenesis in mice. Cancer Lett. 1992, 65, 245-249.
37. Siegers, C. P.; Bumann, D.; Baretton, G.; and Younes, M. Dietary iron enhances the tumor rate in dimethylhydrazine-induced colon carcinogenesis in mice. Cancer Lett. 1988, 41, 251-256.
38. Blum, H. E. Molecular targets for prevention of hepatocellular carcinoma. Dig. Dis. 2002, 20, 81-90.
39. Deugnier, Y. and Turlin, B. Iron and hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2001, 16, 491-494.
40. Yang, D. C.; Jiang, X. P.; Elliott, R. L.; and Head, J. F. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene. Anticancer Res. 2001, 21, 1777-1787.
41. Sasaki, K.; Zak, O.; and Aisen, P. Antisense suppression of transferrin receptor gene expression in a human hepatoma cell (HuH-7) line. Am. J. Hematol. 1993, 42, 74-80.
42. Taetle, R.; Castagnola, J.; and Mendelsohn, J. Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies. Cancer Res. 1986, 46, 1759-1763.
43. Trowbridge, I. S. and Lopez, F. Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc. Natl. Acad. Sci. USA 1982, 79 1175-1179.
44. Kemp, J. D.; Cardillo, T.; Stewart, B. C.; Kehrberg, E.; Weiner, G.; Hedlund, B.; and Naumann, P. W. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. Cancer Res. 1995, 55, 3817-3824.
45. Benbassat, J.; Hershko, C.; Laskov, R.; and Eliakim, M. Effect of iron deficiency on transplantable murine plasmacytoma. Nutr. Cancer 1981, 3, 20-26.
46. Hann, H. W., Stahlhut, M. W.; and Blumberg, B. S. Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. Cancer Res. 1988, 48, 4168-4170.
47. Martell, A. E. and Smith, R. M. Critical Stability Constants; Plenum Press: New York, 1977.
48. Keberle, H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann. N. Y. Acad. Sci. 1964, 119, 758-768.
49. Summers, M. R.; Jacobs, A.; Tudway, D.; Perera, P.; and Ricketts, C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br. J. Haematol. 1979, 42 547-555.
50. Creighton, A. M. Piperazine derivatives. [1,234,935]. 1971. U. K.
51. Hasinoff, B. B. The hydrolysis activation of the doxorubicin cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane)]. Drug Metab. Dispos. 1990, 18, 344-349.
52. Hasinoff, B. B. Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R -enantiomer ICRF-186 by dihydropyrimidine amidohydrolase. Drug Metab. Dispos. 1993, 21, 883-888.
53. Schroeder, P. E.; Davidson, J. N.; and Hasinoff, B. B. Dihydroorotase Catalyzes the Ring Opening of the Hydrolysis Intermediates of the Cardioprotective Drug Dexrazoxane (ICRF-187). Drug Metab. Dispos. 2002, 30, 1431-1435.
54. Huang, Z. X.; May, P. M.; Quinlan, K. M.; Williams, D. R.; and Creighton, A. M. Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192. Agents Actions 1982, 12, 536-542.
55. French, F. A. and Blanz, E. J., Jr. The carcinostatic activity of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. II. 3-Hydroxypyridine-2-carboxaldehyde thiosemicarbazone. Cancer Res. 1966, 26, 1638-1640.
56. Richardson, D. R. and Ponka, P. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J. Lab. Clin. Med. 1998, 131, 306-315.
57. Webb, J. and Vitolo, M. L. Pyridoxal isonicotinoyl hydrazone (PIH): a promising new iron chelator. Birth Defects: Orig. Art. Ser. 1988, 23, 63-70.
58. Tsafack, A.; Loyevsky, M.; Ponka, P.; and Cabantchik, Z. I. Mode of action of iron (III) chelators as antimalarials. IV. Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives. J. Lab. Clin. Med. 1996, 127, 574-582.
59. Golenser, J.; Dumb, A.; Teomim, D.; Tsafack, A.; Nisim, O.; Eling, W.; and Cabantchik, Z. I. The treatment of animal models of malaria with iron chelators by use of a novel polymeric device for slow drug release. J. Pharm. Exp. Ther. 1997, 281, 1127-1135.
60. Richardson, D. R. Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia. Leuk. Lymph. 1998, 31, 47-60.
61. Murphy, T. B.; Johnson, D. K.; Rose, N. J.; Aruffo, A.; and Schomaker, V. Structural studies of iron(III) complexes of the new iron-binding drug, pyridoxal isonicotinoyl hydrazone. Inorg. Chim. Acta 1982, 66, L67-L68.
62. Souron, J. P.; Quarton, M.; Robert, F.; Lyubchova, A.; Cosse-Barbi, A.; and Doucet, J. P. Pyridoxal isonicotinoyl hydrazone (PIH), a synthetic ion-chelating agent. Acta Cryst. Sect, C 1995 51, 2179-2182.
63. Richardson, D. R. and Bernhardt, P. V. Crystal and molecular structure of 2-hydroxy-l-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity. J. Biol. Inorg. Chem. 1999, 4, 266-273.
64. Ponka, P.; Borova, J.; Neuwirt, J.; and Fuchs, O. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett. 1979, 97, 317-321.
65. Becker, E. and Richardson, D. R. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. J. Lab. Clin. Med. 1999, 134, 510-521.
66. Lovejoy, D. B. and Richardson, D. R. Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood 2002, 100, 666-676.
67. Samuni, A. M.; Krishna, M. C.; DeGraff, W.; Russo, A.; Planalp, R. P.; Brechbiel, M. W.; and Mitchell, J. B. Mechanisms underlying the cytotoxic effects of Tachpyr - a novel metal chelator. Biochim. Biophys. Acta 2002, 1571, 211-218.
68. Park, G.; Lu, F. H.; Ye, N.; Brechbiel, M. W.; Torti, S. V.; Torti, F. M.; and Planalp, R. P. Novel iron complexes and chelators based on c i s,cis-1,3,5-triaminocyclohexane: iron-mediated ligand oxidation and biochemical properties. J. Biol. Inorg. Chem. 1998 3, 449-457.
69. Planalp, R. P.; Przyborowska, A. M.; Park, G.; Ye, N.; Lu, F. H.; Rogers, R. D.; Broker, G. A.; Torti, S. V.; and Brechbiel, M. W. Novel cytotoxic chelators that bind iron(II) selectively over zinc(II) under aqueous aerobic conditions. Biochem. Soc. Trans. 2002, 30, 758-762.
70. II) potentially suitable for plant nutrition and iron chelation therapy. J. Am. Chem. Soc. 1995, 117, 9760-9761.
71. Caris, C.; Baret, P.; Beguin, C.; Serratrice, G.; Pierre, J. L.; and Laulhere, J. P. Metabolization of iron by plant cells using O-Trensox, a high-affinity abiotic iron-chelating agent. Biochem. J. 1995, 312 (Pt 3), 879-885.
72. Anderegg, G. and Raber, M. Metal complex formation of a new siderophore desferrithiocin and of three related ligands. J. Chem. Soc. Chem. Commun. 1990, 1194-1196.
73. Cable, H. and Lloyd, J. B. Cellular uptake and release of two contrasting iron chelators. Journal of Pharmacy and Pharmacology 1999, 51, 131-134.
74. Richardson, D. R.; Tran, E. H.; and Ponka, P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995, 86, 4295-4306.
75. Chaston, T. B.; Lovejoy, D. B.; Watts, R. N.; and Richardson, D. R. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin. Cancer Res. 2003, 9, 402-414.
76. Weiss, G.; Kastner, S.; Brock, J.; Thaler, J.; and Grunewald, K. Modulation of transferrin receptor expression by dexrazoxane (ICRF-187) via activation of iron regulatory protein. Biochem. Pharmacol. 1997, 53, 1419-1424.
77. Kim, S. and Ponka, P. Effects of interferon-gamma and lipopolysaccharide on macrophage iron metabolism are mediated by nitric oxide-induced degradation of iron regulatory protein 2. J. Biol. Chem. 2000, 275, 6220-6226.
78. Rakba, N.; Aouad, F.; Henry, C.; Caris, C.; Morel, I.; Baret, P.; Pierre, J. L.; Brissot, P.; Ward, R. J.; Lescoat, G.; and Crichton, R. R. Iron mobilisation and cellular protection by a new synthetic chelator O-Trensox. Biochem. Pharmacol. 1998, 55, 1797-1806.
79. Baker, E.; Wong, A.; Peter, H.; and Jacobs, A. Desferrithiocin is an effective iron chelator in vivo and in vitro but ferrithiocin is toxic. Br. J. Haematol. 1992, 81, 424-431.
80. Buss, J. L.; Arduini, E.; and Ponka, P. Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes. Biochem. Pharmacol. 2002, 64, 1689-1701.
81. Semenza, G. L. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001, 107, 1-3.
82. 2 tension. Proc. Natl. Acad. Sci. USA 1995, 92, 5510-5514.
83. O'Rourke, J. F.; Pugh, C. W.; Bartlett, S. M.; and Ratcliffe, P. J. Identification of hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role of hypoxia-inducible factor-1. Eur. J. Biochem. 1996, 241, 403-410.
84. Warnecke, C.; Griethe, W.; Weidemann, A.; Jurgensen, J. S.; Willam, C.; Bachmann, S.; Ivashchenko, Y.; Wagner, I.; Frei, U.; Wiesener, M.; and Eckardt, K. U. Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J. 2003, 17, 1186-1188.
85. Linden, T.; Katschinski, D. M.; Eckhardt, K.; Scheid, A.; Pagel, H.; and Wenger, R. H. The antimycotic ciclopirox olamine induces HIF-1α stability, VEGF expression, and angiogenesis. FASEB J. 2003, 17, 761-763.
86. Templeton, D. M. and Liu, Y. Genetic regulation of cell function in response to iron overload or chelation. Biochim. Biophys. Acta 2003, 1619, 113-124.
87. Bruick, R. K. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl. Acad. Sci. U. S. A 2000, 97, 9082-9087.
88. Nyholm, S.; Mann, G. J.; Johansson, A. G.; Bergeron, R. J., Graslund, A.; and Thelander, L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J. Biol. Chem. 1993, 268, 26200-26205.
89. Sartorelli, A. C.; Agrawal, K. C.; and Moore, E. C. Mechanism of inhibition of ribonucleoside diphosphate reductase by α -(N -heterocyclic aldehyde thiosemicarbazones. Biochem. Pharmacol. 1971, 20, 3119-3123.
90. Moore, E. C.; Zedeck, M. S.; Agrawal, K. C.; and Sartorelli, A. C. Inhibition of ribonucleoside diphosphate reductase by 1-formylisoquinoline thiosemicarbazone and related compounds. Biochemistry 1970, 9, 4492-4498.
91. Cory, A. H.; Sato, A.; Thompson, D. P.; and Cory, J. G. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formyl-isoquinoline thiosemicarbazone. Oncol. Res. 1996, 8, 449-456.
92. Green, D. A.; Antholine, W. E., Wong, S. J.; Richardson, D. R.; and Chitambar, C. R. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase. Clin. Cancer Res. 2001, 7, 3574-3579.
93. Lederman, H. M.; Cohen, A.; Lee, J. W.; Freedman, M. H.; and Gelfand, E. W. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 1984, 64, 748-753.
94. Sartorelli, A. C.; Agrawal, K. C.; Tsiftsoglou, A. S.; and Moore, E. C. Characterization of the biochemical mechanism of action of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Adv. Enzyme Regul. 1976, 15, 117-139.
95. Thelander, L. and Graslund, A. Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone. Destruction of the tyrosine free radical of the enzyme in an oxygen-requiring reaction. J. Biol. Chem. 1983, 258, 4063-4066.
96. Preidecker, P. J.; Agrawal, K. C.; Sartorelli, A. C.; and Moore, E. C. Effects of the ferrous chelate of 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone (MAIQ-1) on the kinetics of reduction of CDP by ribonucleotide reductase of the Novikoff tumor. Mol. Pharmacol. 1980, 18, 507-512.
97. Saryan, L. A.; Ankel, E.; Krishnamurti, C.; Petering, D. H.; and Elford, H. Comparative cytotoxic and biochemical effects of ligands and metal complexes of α-N-heterocyclic carboxaldehyde thiosemicarbazones. J. Med. Chem. 1979, 22, 1218-1221.
98. Cory, J. G.; Cory, A. H.; Rappa, G.; Lorico, A.; Liu, M. C.; Lin, T. S.; and Sartorelli, A. C. Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem. Pharmacol. 1994, 48, 335-344.
99. Richardson, D. R. and Milnes, K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaidehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 1997, 89, 3025-3038.
100. Yataganas, X.; Strife, A.; Perez, A.; and Clarkson, B. Cell kill kinetics with hydroxyurea. Med Pediatr. Oncol. 1976, 2, 39-54.
101. Kato, J.; Kohgo, Y.; Kondo, H.; Sasaki, K.; and Niitsu, Y. Antisense oligodeoxynucleotides for IL-2, c-myc and transferrin receptor synchronize mitogen-activated lymphocytes in the G1 phase. Scand. J. Immunol. 1994, 39, 499-504.
102. Kakhlon, O.; Gruenbaum, Y.; and Cabantchik, Z. I. Ferritin expression modulates cell cycle dynamics and cell responsiveness to H-ras-induced growth via expansion of the labile iron pool. Biochem. J. 2002, 363, 431-436.
103. Renton, F. J. and Jeitner, T. M. Cell cycle-dependent inhibition of the proliferation of human neural tumor cell lines by iron chelators. Biochem. Pharmacol. 1996, 51, 1553-1561.
104. Gao, J. and Richardson, D. R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood 2001, 98, 842-850.
105. Lucas, J. J.; Szepesi, A.; Domenico, J.; Takase, K.; Tordai, A.; Terada, N.; and Gelfand, E. W. Effects of iron-depletion on cell cycle progression in normal human T lymphocytes: selective inhibition of the appearance of the cyclin A-associated component of the p33cdk2 kinase. Blood 1995, 86, 2268-2280.
106. Kulp, K. S.; Green, S. L.; and Vulliet, P. R. Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells. Exp. Cell Res. 1996, 229, 60-68.
107. Le, N. T. and Richardson, D. R. Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation. Carcinogenesis 2003, 24, 1045-1058.
108. Abeysinghe, R. D.; Greene, B. T.; Haynes, R.; Willingham, M. C.; Turner, J.; Planalp, R. P.; Brechbiel, M. W.; Torti, F. M.; and Torti, S. V. p53-independcnt apoptosis mediated by tachpyridine, an anticancer iron chelator. Carcinogenesis 2001, 22, 1607-1614.
109. Alcantara, O.; Kalidas, M.; Baltathakis, I.; and Boldt, D. H. Expression of multiple genes regulating cell cycle and apoptosis in differentiating hematopoietic cells is dependent on iron. Exp. Hematol. 2001, 29, 1060-1069.
110. Fukuchi, K.; Tomoyasu, S.; Watanabe, H.; Tsuruoka, N.; and Gomi, K. G1 accumulation caused by iron deprivation with deferoxamine does not accompany change of pRB status in ML-1 cells. Biochim. Biophys. Acta 1997, 1357, 297-305.
111. Spasojevic, I.; Armstrong, S. K.; Brickman, T. J.; and Crumbliss, A. L. Electrochemical Behavior of the Fe(III) Complexes of the Cyclic Hydroxamate Siderophores Alcaligin and Desferrioxamine E. Inorg. Chem 1999, 38, 449-454.
112. Emerit, J.; Beaumont, C.; and Trivin, F. Iron metabolism, free radicals, and oxidative injury. Biomed. Pharmacother. 2001 55, 333-339.
113. Schulman, H. M.; Hermes-Lima, M.; Wang, E. M.; and Ponka, P. In vitro antioxidant properties of the iron chelator pyridoxal isonicotinoyl hydrazone and some of its analogs. Redox Rep. 1995 1, 373-378.
114. Bhattacharya, M.; Ponka, P.; Hardy, P.; Hanna, N.; Varma, D. R.; Lachapelle, P.; and Chemtob, S. Prevention of postasphyxia electroretinal dysfunction with a pyridoxal hydrazone. Free Rad. Biol. Med. 1997, 22, 11-16.
115. Buss, J. L.; Arduini, E.; Shephard, K. C.; and Ponka, P. Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells. Biochem. Pharmacol. 2003, 65, 349-360.
116. Ferrali, M.; Signorini, C.; Ciccoli, L.; Bambagioni, S.; Rossi, V.; Pompella, A.; and Comporti, M. Protection of erythrocytes against oxidative damage and autologous immunoglobulin G (IgG) binding by iron chelator fluor-benzoil-pyridoxal hydrazone. Biochem. Pharmacol. 2000, 59, 1365-1373.
117. Buss, J. L. and Hasinoff, B. B. Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187). Arch. Biochem. Biophys. 1995, 317, 121-127.
118. Chaston, T. B. and Richardson, D. R. Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease. J. Biol. Inorg. Chem 2003, 8, 427-438.
119. Buss, J. L.; Arduini, E.; Shephard, K. C.; and Ponka, P. Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines efflux of Fe complexes, which determines their chelating efficiency and toxicity in K562 cells. Biochem. Pharmacol. 2002.
120. Buss, J. L.; Neuzil, J.; Gellert, N.; Weber, C.; and Ponka, P. Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties. Biochem. Pharmacol. 2003, 65, 161-172.
121. Forsbeck, K.; Bjelkenkrantz, K.; and Nilsson, K. Role of iron in the proliferation of the established human tumor cell lines U-937 and K-562: effects of suramin and a lipophilic iron chelator (PIH). Scand. J. Haematol. 1986, 37, 429-437.
122. Tsao, M. S.; Sanders, G. H.; and Grisham, J. W. Regulation of growth of cultured hepatic epithelial cells by transferrin. Exp. Cell Res. 1987, 171, 52-62.
123. Brock, J. H. and Stevenson, J. Replacement of transferrin in serum-free cultures of mitogen-stimulated mouse lymphocytes by a lipophilic iron chelator. Immunol. Lett. 1986, 15, 23-25.
124. Hasinoff, B. B.; Hellmann, K.; Herman, E. H.; and Ferrans, V. J. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr. Med. Chem. 1998, 5, 1-28.
125. Buss, J. L. and Hasinoff, B. B. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions 1993, 40, 86-95.
126. Barnabe, N.; Zastre, J. A.; Venkataram, S.; and Hasinoff, B. B. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Rad. Biol. Med. 2002, 33, 266-275.
127. Saad, S. Y.; Najjar, T. A.; and Al Rikabi, A. C. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol. Res. 2001, 43, 211-218.
128. Kaplinsky, C.; Estrov, Z.; Freedman, M. H.; Gelfand, E. W.; and Cohen, A. Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells. Leukemia 1987 1, 437-441.
129. Tanaka, T.; Muto, N.; Ido, Y.; Itoh, N.; and Tanaka, K. Induction of embryonal carcinoma cell differentiation by deferoxamine, a potent therapeutic iron chelator. Biochim. Biophys. Acta 1997 1357, 91-97.
130. Gambari, R.; Raschella, G.; Tripodi, M.; Farace, M. G.; and Fantoni, A. Desferrioxamine inhibits induced erythroid differentiation of human leukemic K-562 cells. Cell Differ. 1983, 12, 249-255.
131. Wilson, M. R. Apoptotic signal transduction: emerging pathways. Biochem. Cell Biol. 1998, 76, 573-582.
132. Simonart, T.; Degraef, C.; Andrei, G.; Mosselmans, R.; Hermans, P.; Van Vooren, J. P.; Noel, J. C.; Boelaert, J. R.; Snoeck, R.; and Heenen, M. Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors. J. Invest. Dermatol. 2000, 115, 893-900.
133. Kim, B. S.; Yoon, K. H.; Oh, H. M.; Choi, E. Y.; Kim, S. W.; Han, W. C.; Kim, E. A.; Choi, S. C.; Kim, T. H.; Yun, K. J.; Kim, E. C.; Lyou, J. H.; Nah, Y. H.; Chung, H. T.; Cha, Y. N.; and Jun, C. D. Involvement of p38 MAP kinase during iron chelator-mediated apoptotic cell death. Cell Immunol. 2002, 220, 96-106.
134. Mizutani, A.; Furukawa, T.; Adachi, Y.; Ikehara, S.; and Taketani, S. A zinc-finger protein, PLAGL2, induces the expression of a proapoptotic protein Nip3, leading to cellular apoptosis. J. Biol. Chem 2002, 277, 15851-15858.
135. Rakba, N.; Loyer, P.; Gilot, D.; Delcros, J. G.; Glaise, D.; Baret, P.; Pierre, J. L.; Brissot, P.; and Lescoat, G. Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. Carcinogenesis 2000 21, 943-951.
136. Yu, Z.; Persson, H. L.; Eaton, J. W.; and Brunk, U. T. Intralysosomal iron: a major determinant of oxidant-induced cell death. Free Radic. Biol. Med. 2003, 34, 1243-1252.
137. O'Connor, P. M.; Jackman, J.; Bae, I.; Myers, T. G.; Fan, S.; Mutoh, M.; Scudiero, D. A.; Monks, A.; Sausville, E. A.; Weinstein, J. N.; Friend, S.; Fornace, A. J., Jr.; and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997, 57, 4285-4300.
138. Greene, B. T.; Thorburn, J.; Willingham, M. C.; Thorburn, A.; Planalp, R. P.; Brechbiel, M. W.; Jennings-Gee, J.; Wilkinson, J.; Torti, F. M.; and Torti, S. V. Activation of caspase pathways during iron chelator-mediated apoptosis. J. Biol. Chem. 2002, 277, 25568-25575.
139. Hann, H. W.; Stahlhut, M. W.; Rubin, R.; and Maddrey, W. C. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer 1992, 70, 2051-2056.
140. Selig, R. A.; White, L.; Gramacho, C.; Sterling-Levis, K.; Fraser, I. W.; and Naidoo, D. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. Cancer Res. 1998, 58, 473-478.
141. Simonart, T.; Boelaert, J. R.; Andrei, G.; Clercq, E. D.; and Snoeck, R. Iron withdrawal strategies fail to prevent the growth of SiHa-induced tumors in mice. Gynecol. Oncol. 2003, 90, 91-95.
142. Dragsten, P. R.; Hallaway, P. E.; Hanson, G. J.; Berger, A. E.; Bernard, B.; and Hedlund, B. E. First human studies with a high-molecular-weight iron chelator. J. Lab Clin. Med. 2000, 135, 57-65.
143. Sartorelli, A. C. and Creasey, W. A. Cancer chemotherapy. Annu. Rev. Pharmacol. 1969, 9, 51-72.
144. Creasey, W. A.; Agrawal, K. C.; Capizzi, R. L.; Stinson, K. K.; and Sartorelli, A. C. Studies of the antineoplastic activity and metabolism of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones in dogs and mice. Cancer Res. 1972, 32, 565-572.
145. French, F. A. and Blanz, E. J., Jr. The carcinostatic activity of α-(N) heterocyclic carboxaldehyde thiosemicarbazones. I. Isoquinoline-1-carboxaldehyde thiosemicarbazone. Cancer Res. 1965, 25, 1454-1458.
146. Finch, R. A.; Liu, M.; Grill, S. P.; Rose, W. C.; Loomis, R.; Vasquez, K. M.; Cheng, Y.; and Sartorelli, A. C. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol. 2000, 59, 983-991.
147. Liu, M. C.; Lin, T. S.; and Sartorelli, A. C. Synthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. J. Med. Chem. 1992, 35, 3672-3677.
148. Tarao, K.; Shimizu, A.; Ohkawa, S.; Harada, M.; Ito, Y.; Tamai, S.; Kuni, Y.; Okamoto, N.; Inoue, T.; and Kanisawa, M. Development of hepatocellular carcinoma associated with increases in DNA synthesis in the surrounding cirrhosis. Gastroenterol. 1992, 103, 595-600.
149. Ballardini, G.; Groff, P.; Zoli, M.; Bianchi, G.; Giostra, F.; Francesconi, R.; Lenzi, M.; Zauli, D.; Cassani, F.; and Bianchi, F. Increased risk of hepatocellular carcinoma development in patients with cirrhosis and with high hepatocellular proliferation. J. Hepatol. 1994, 20, 218-222.
150. Wolfe, L. C.; Nicolosi, R. J.; Renaud, M. M.; Finger, J.; Hegsted, M.; Peter, H.; and Nathan, D. G. A non-human primate model for the study of oral iron chelators. Br. J. Haematol. 1989, 72, 456-461.
151. Longueville, A. and Crichton, R. R. An animal model of iron overload and its application to study hepatic ferritin iron mobilization by chelators. Biochem. Pharmacol. 1986, 35, 3669-3678.
152. Bergeron, R. J.; Wiegand, J.; Dionis, J. B,; Egli-Karmakka, M.; Frei, J.; Huxley-Tencer, A.; and Peter, H. H. Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators. J. Med. Chem. 1991, 34, 2072-2078.
153. Hershko, C.; Avramovici-Grisaru, S.; Link, G.; Gelfand, L.; and Sarel, S. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J. Lab. Chn. Med. 1981, 98, 99-108.
154. Johnson, D. K.; Pippard, M. J.; Murphy, T. B.; and Rose, N. J. An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs. J. Pharm. Exp. Ther. 1982, 221 399-403.
155. Williams, A.; Hoy, T.; Pugh, A.; and Jacobs, A. Pyridoxal complexes as potential chelating agents for oral therapy in transfusional iron overload. J. Pharm. Pharmacol. 1982, 34, 730-732.
156. Avramovici-Grisaru, S.; Sarel, S.; Link, G.; and Hershko, C. Syntheses of iron bis(pyridoxal isonicotinoylhydrazone)s and the in vivo iron-removal properties of some pyridoxal derivatives. J. Med. Chem. 1983, 26, 298-302.
157. Cikrt, M.; Ponka, P.; Necas, E.; and Neuwirt, J. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Br. J. Haematol. 1980, 45, 275-283.
158. Blaha, K.; Cikrt, M.; Nerudova, J.; Fornuskova, H.; and Ponka, P. Biliary iron excretion in rats following treatment with analogs
159. Estrov, Z.; Tawa, A.; Wang, X. H.; Dube, I. D.; Sulb, H.; Cohen, A.; Gelfand, E. W.; and Freedman, M. H. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 1987 69, 757-761.
160. Dezza, L.; Cazzola, M.; Danova, M.; Carlo-Stella, C.; Bergamaschi, G.; Brugnatelli, S.; Invernizzi, R.; Mazzini, G.; Riccardi, A.; and Ascari, E. Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies. Leukemia 1989, 3, 104-107.
161. Donfrancesco, A.; Deb, G.; Dominici, C.; Pileggi, D.; Castello, M. A.; and Helson, L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res. 1990, 50, 4929-4930.
162. Blatt, J. Deferoxamine in children with recurrent neuroblastoma. Anticancer Res. 1994, 14, 2109-2112.
163. Donfrancesco, A.; De Bernardi, B.; Carli, M.; Mancini, A.; Nigro, M.; De Sio, L.; Casale, F.; Bagnulo, S.; Helson, L.; and Deb, G. Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group. Eur. J. Cancer 1995, 31A, 612-615.
164. Donfrancesco, A.; Deb, G.; Angioni, A.; Maurizio, C.; Cozza, R.; Jenkner, A.; Landolfo, A.; Boglino, C.; and Helson, L. D-CECaT: a breakthrough for patients with neuroblastoma. Anticancer Drugs 1993, 4, 317-321.
165. DeConti, R. C.; Toftness, B. R.; Agrawal, K. C.; Tomchick, R.; Mead, J. A.; Bertino, J. R.; Sartorelli, A. C.; and Creasey, W. A. Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone. Cancer Res. 1972, 32, 1455-1462.
166. Feun, L.; Modiano, M., Lee, K.; Mao, J.; Marini, A.; Savaraj, N.; Plezia, P.; Almassian, B.; Colacino, E.; Fischer, J.; and MacDonald, S. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother. Pharmacol. 2002, 50, 223-229.
167. Creighton, A. M.; Hellmann, K.; and Whitecross, S. Antitumour activity in a series of bisdiketopiperazines. Nature 1969, 222, 384-385.
168. Speyer, J. L.; Green, M. D.; Kramer, E.; Rey, M.; Sanger, J.; Ward, C.; Dubin, N.; Ferrans, V.; Stecy, P.; and Zeleniuch-Jacquotte, A. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. New Engl. J. Med. 1988, 319, 745-752.
169. Lemez, P. and Maresova, J. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy. Semin. Hematol. 1998, 25 61-65.
170. Serratrice, G.; Boukhalfa, H.; Beguin, C.; Baret, P.; Caris, C.; and Pierre, J. L. O-Trensox, a new tripodal iron chelator based on 8-hydroxyquinoline subunits: thermodynamic and kinetic studies. Inorg. Chem. 1997, 36, 3898-3910.
171. Diop, N. K.; Vitellaro, L. K.; Arnold, P.; Shang, M.; and Marusak, R. A. Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity. J. Inorg. Biochem. 2000, 78, 209-216.
172. Buss, J. L. and Ponka, P. Hydrolysis of pyridoxal isonicotinoyl hydrazone and its analogs. Biochim., Biophys. Acta 2003, 1619, 177-186.